4 October 2016 - Increased proportion of treatment-change limits further interpretability so the results of the initial IQWiG evaluation shall continue.

Crizotinib (Xalkori) has been available since 2012 for the second-line treatment of patients with advanced non-small-cell lung cancer with high activity of the enzyme anaplastic lymphoma kinase. Crizotinib has already undergone a dossier evaluation for such use. The G-BA limited its decision, which is why the manufacturer has submitted another dossier.

The IQWiG has now assessed this second dossier: For patients who are eligible for treatment with chemotherapy, it contains new results. These data cannot be interpreted meaningfully.

For other patients, the manufacturer did not present any new data. The result of the first dossier evaluation therefore remains unchanged.

Read IQWiG press release [German]